JP Morgan 2023

January 5, 2023 AutoBot 0

For most people, the name “JP Morgan” means bankers and investors. But for the pharma sector, it means meetings all over town in San Francisco […]

No Image

Corrigendum

January 5, 2023 AutoBot 0

Annals of Pharmacotherapy, Volume 57, Issue 9, Page 1124-1124, September 2023.

No Image

New tentative approval for Amneal Pharms drug saxagliptin

January 5, 2023 AutoBot 0

[![saxagliptin structure](https://www.DrugPatentWatch.com/img/drug-structure/saxagliptin.png)](//www.DrugPatentWatch.com/p/preview/generic-api/saxagliptin?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents […]

No Image

New tentative approval for Teva Pharms drug eltrombopag

January 5, 2023 AutoBot 0

[![eltrombopag structure](https://www.DrugPatentWatch.com/img/drug-structure/eltrombopag.png)](//www.DrugPatentWatch.com/p/preview/generic-api/eltrombopag?utm_medium=dpw_wp_blog&utm_campaign=dpw_wp_blog&utm_source=dpw_wp_blog) Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting […]

No Image

2022 Publications

January 4, 2023 AutoBot 0

As we have turned the leaf to 2023, I figured I’d share the publications I had last year: Publications Forma F, Chiu K, Shafrin J, […]